-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Diabetic Macular Edema Drug Details: Tonabersat (HCB-1019) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Diabetic Nephropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Diabetic Nephropathy Drug Details: Tonabersat (HCB-1019) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Dry (Atrophic) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Dry (Atrophic) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Dry (Atrophic) Macular Degeneration Drug Details: Tonabersat (HCB-1019)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration...
-
Product Insights
Myocardial Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Ischemia - Drugs In Development, 2023’, provides an overview of the Myocardial Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Polmacoxib + Tramadol) in Osteoarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Polmacoxib + Tramadol) in Osteoarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Polmacoxib + Tramadol) in Osteoarthritis Drug Details:CG-650 is a fixed dose combination...
-
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The Age...